PriceTargets.com logo

Bradmer Pharmaceuticals - GLX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 5 Strong Buy Ratings
C$0.00 As of 12/20/2023 05:51 AM ET
+0 (0.00%)

This chart shows the closing price for GLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bradmer Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLX

Analyst Price Target is C$0.00
This price target is based on 8 analysts offering 12 month price targets for Bradmer Pharmaceuticals in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a NaN upside from the last price of C$0.00.

This chart shows the closing price for GLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Bradmer Pharmaceuticals. This rating changed within the last month from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 2 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 4 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 6 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 5 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2025
  • 6 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2026
  • 5 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2026

Latest Recommendations

  • 5 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/24/2026CitigroupUpgradeHold
2/5/2026ATB Cormark Capital MarketsDowngradeStrong-Buy ➝ Moderate Buy
12/9/2025Citizens JmpUpgradeStrong-Buy
7/31/2025Maxim GroupUpgradeStrong-Buy
7/31/2025The Goldman Sachs GroupUpgradeHold
6/24/2025Rosenblatt SecuritiesUpgradeStrong-Buy
4/14/2025BTIG ResearchUpgradeStrong-Buy
3/31/2025BenchmarkUpgradeStrong-Buy
2/25/2025Cantor FitzgeraldUpgradeStrong-Buy
1/29/2025Cantor FitzgeraldUpgradeStrong-Buy
10/10/2024HC WainwrightUpgradeStrong-Buy
3/13/2024Stifel NicolausReiterated RatingBuy
12/15/2023ATB Cormark Capital MarketsReiterated RatingOutperform
(Data available from 3/5/2021 forward)

News Sentiment Rating

1.08 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/4/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/3/2026
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/5/2026

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Bradmer Pharmaceuticals logo
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Bradmer Pharmaceuticals?

The following equities research analysts have issued reports on Bradmer Pharmaceuticals in the last year: ATB Cormark Capital Markets, Benchmark Co., BTIG Research, Citigroup Inc., Citizens Jmp, Maxim Group, Rosenblatt Securities, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for GLX.

What is the current price target for Bradmer Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Bradmer Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Bradmer Pharmaceuticals in the next year.
View the latest price targets for GLX.

What is the current consensus analyst rating for Bradmer Pharmaceuticals?

Bradmer Pharmaceuticals currently has 2 hold ratings, 1 buy rating and 5 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GLX will outperform the market and that investors should add to their positions of Bradmer Pharmaceuticals.
View the latest ratings for GLX.

How do I contact Bradmer Pharmaceuticals' investor relations team?

Bradmer Pharmaceuticals' physical mailing address is C/O PATTERSON BELKNAP C/O H. RASPE, 1133 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036. The company's listed phone number is (212) 336-2301. The official website for Bradmer Pharmaceuticals is n. Learn More about contacing Bradmer Pharmaceuticals investor relations.